Suzhou Meichuang Medical Secures Over RMB 200 Million in Series B Financing Within Six Months, WinX Capital Serves as Exclusive Financial Advisor

VCBeat has learned that,Recently, MEImedical(hereinafter referred to as “MEImedical”), announced the completion of anotherBySuzhou Venture Capital, jointly funded by investors including Paradise Silicon Valley, Guanghua Wutong, and MedparkEquity Financing in the Hundreds of Millions of Yuan,WinX Capital Continues to Serve as the Exclusive Financial Advisor,Following the over RMB 100 million investment received by MEImedical in January 2025 from investors including Sequoia China, Yifeng Capital, Industrial Securities Capital, and Qingsong Capital, the company has once again gained recognition from prominent capital firms. Having secured cumulative investments exceeding RMB 200 million within six months, this achievement fully demonstrates investors’ strong endorsement of MEImedical’s industry standing.

Founded in 2021 in Suzhou High-Tech Zone by Mr. Liu Wenjing, who boasts over 30 years of experience in the peripheral vascular and tumor intervention industries, MEImedical marks Mr. Liu’s second entrepreneurial venture. Prior to establishing MEImedical, the founder had established Shanghai Meichuang in 2004. Constrained by the declining market competitiveness of imported medical products under the volume-based procurement (VBP) regime, as well as the successive acquisitions of his company’s product lines—where it served as the China general distributor—by multinational giants, the founder resolutely leveraged his extensive accumulated expertise to establish MEImedical. The company is committed to developing a pipeline of peripheral vascular and tumor intervention products better tailored to the needs of Chinese patients.

MEImedical has achieved commercial production and mass manufacturing of medical-grade expanded polytetrafluoroethylene (ePTFE) materials for implantation, becoming the first Chinese manufacturer in the industry to overcome the critical bottleneck associated with these materials. To date, the company has completed the master file registration with China’s National Medical Products Administration (NMPA) for ePTFE tubing and membrane products. Leveraging the vast application scenarios of ePTFE, MEImedical has also collaborated with multiple device manufacturers across specialized medical sectors to customize and implement the updating and replacement of ePTFE materials. This initiative helps more medical device companies address the longstanding challenges posed by overseas suppliers—namely high prices, long lead times, and refusal to accommodate customization—thereby mitigating supply chain risks amid a complex international landscape.

The recognition from multiple investment institutions will strengthen MEImedical’s commercialization strategy. The company’s self-developed products, based on ePTFE materials and other core technology platforms, are accelerating through clinical trials and regulatory registration. Some products have already received approval and entered formal commercialization. Leveraging a mature marketing system and strong financial resources, the company’s products are poised to rapidly gain a foothold in the domestic and international markets for peripheral vascular and tumor intervention medical devices.

Liu Wenjing, Founder of MEImedicalIndicates:Just five months later, we are honored to once again gain recognition and support from multiple renowned investment institutions. This not only serves as a strong affirmation of our technology platform and business model, but also reflects the capital market’s firm confidence in the trend toward localization of high-end medical devices. Moving forward, we will continue to prioritize technological innovation as our core driver, strengthen our capabilities in product registration, clinical translation, and manufacturing, and accelerate the global deployment of our core products.

We extend our gratitude to all investors, partners, and team members for their trust and steadfast support. We are committed to living up to these expectations by remaining patient-centric in our mission to become a world-class medical technology company.。

Heavenly Silicon Valley stated:We have consistently focused on investment opportunities in the vascular health sector driven by population aging. Leveraging the founding team’s long-standing first-mover advantage in this field, MEImedical has not only established a well-structured product R&D portfolio but also mastered the manufacturing technology for ePTFE, a critical upstream material. We believe that with the support of this financing round, MEImedical will accelerate its growth trajectory and bring benefits to a broad patient population at an earlier stage.

Guanghua WutongHead of InvestmentIndicates:We are highly optimistic about the development of the peripheral vascular sector in China. Fortunately, through its independent research and development of ePTFE, MEImedical has further solidified its competitiveness in this field. Leveraging its excellent international R&D team and experienced commercialization team, we believe that the company will develop more exciting, high-quality products that truly meet clinical needs in the future.

Medpark stated:We are pleased to provide funding support to MEImedical, a star enterprise at our Jiangsu Medical Device Technology Industrial Park (Medpark). China needs more companies like MEImedical that possess core foundational technologies and commercialization capabilities. We believe the company is poised to become an outstanding platform-based leader in the peripheral vascular field.

Luo Binhai, Co-Head of Medical Devices at WinX Capital, stated:We are honored to have supported MEImedical in exceeding its fundraising targets for this round. Despite the significant challenges posed by the current uncertain external environment, the company successfully secured over RMB 200 million in financing, leveraging its unique development strategy and the team’s solid resource accumulation. This achievement reflects the strong confidence and steadfast support of both new and existing shareholders in the team’s capabilities and the sector’s potential. We look forward to seeing the company capitalize on this momentum, empowered by its shareholders, to accelerate the commercialization of multiple core products.

Suzhou Innovation Investment Group Co., Ltd. (hereinafter referred to as “Su Chuangtou”) was established on June 18, 2022. Currently, Su Chuangtou oversees eight major entities: Suzhou Guofa Venture Capital, Suzhou Science and Technology Innovation Investment, Suzhou Industrial Investment, Suzhou Angel Fund of Funds, Suzhou Fund, Suzhou Industrial Technology Research Institute, Suzhou Science and Technology Investment Promotion Center, and Suzhou Strategic Emerging Industries Fund. The group has a registered capital of RMB 18 billion, with cumulative assets under management exceeding RMB 260 billion, and holds an AAA principal credit rating.

Suzhou Venture Capital Group (SVC) has clear and well-defined investment directions that align with national development strategies and Suzhou’s industrial priorities. By strategically allocating state-owned capital at the municipal level, SVC promotes horizontal collaboration between regional state-owned assets and central state-owned enterprises, fostering a cooperative framework and resource mobilization within a broader state-owned asset system. Through the establishment of an integrated capital operation platform, SVC effectively coordinates financial and industrial resources, driving synergistic collaboration across various sectors and building an innovative capital network characterized by citywide coordination in Suzhou. In domestic rankings of prominent venture capital firms, SVC has consistently ranked among the top for many years. Its domestic influence has significantly increased, gradually establishing it as a leading, capable, and influential fund brand in China.

Paradise Silicon Valley Venture Capital Group Co., Ltd. (hereinafter referred to as the “Company”) was established in November 2000. The Company was invested and established by four public companies—Silicon Valley Paradise (833044), Qianjiang Water Resources (600283), Zhejiang Orient (600120), and Minfeng Special Paper (600235)—as controlling shareholders, along with other shareholders. Its paid-in capital amounts to RMB 1.2 billion. Headquartered in Hangzhou, the Company maintains offices in Shanghai, Beijing, and other locations.

As one of the first 50 private equity fund managers in China, Paradise Silicon adheres to the business philosophy of “Investors First, Value Investment, and Industry Focus,” concentrating on venture capital investments in three key sectors: intelligent technology, advanced manufacturing, and healthcare. To date, the company and its managed funds have invested in over 230 equity projects, with 51 of the portfolio companies listed on the A-share, Hong Kong Stock Exchange, and U.S. stock markets.

Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd. is a licensed institution under Chengdu Guanghua Kaiyuan Company, specializing in private equity fund management, and the first state-owned capital private equity fund manager in Wenjiang District. Operating within the overall business framework of Guanghua Kaiyuan Company, it is responsible for the management of government investment funds and the market-oriented investment and operation of funds. The company has deep expertise in investing in the biopharmaceutical industry, primarily engaging in fund investments and direct project investments. With assets under management exceeding RMB 9 billion, the company has partnered with leading enterprises, listed companies, and investment institutions to establish more than 20 investment funds, with a total scale exceeding RMB 45 billion.

Jiangsu Medical Device Science and Technology Industrial Park (Medpark) is a national-level medical device science and technology industrial park jointly established by Suzhou New District and the Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences. The operating entity is Suzhou Medical Device Industry Development Group Co., Ltd., which is responsible for coordinating resources in Suzhou New District, with its core business focused on investment and operation in the medical device and biopharmaceutical industries, particularly emphasizing the development of the medical device sector. It has successively been approved as a National Torch Program Characteristic Industrial Base for Medical Devices, a Pilot Zone for National Innovative Medical Device Industry Clusters, a National-Level Professional Incubator for Medical Devices, and a Demonstration Unit for the Construction of National-Level Sci-Tech Entrepreneurship Incubation Chains.

The industrial park covers a total planned area of 2 square kilometers, fully implementing the “one park, one specialty” concept. It has currently laid out six phases of construction, with a total self-built facility area of nearly 1.2 million square meters, which is expected to reach 1.6 million square meters by 2025. The park has gathered international giants in the medical device sector, including bioMérieux, Thermo Fisher Scientific, HOYA Corporation, and Intuitive Surgical, while also attracting investment and mergers and acquisitions from more than ten listed industry leaders such as Yuwell Medical, Weigao Group, and Hengrui Medicine. Key introductions include Euclid Systems, Huayue Health, HeartGear Medical, Nuoyi Mai'er, and Kossel....and other innovative medical device enterprises. Currently, it has gathered more than 1,400 medical device and biopharmaceutical companies, with an industrial output value exceeding RMB 50 billion and an average annual growth rate of over 30%. Its products cover fields such as medical imaging, biomedical materials, in vitro diagnostics (IVD), and medical robots, with numerous technological achievements being first-of-their-kind in China and leading the industry. It now holds more than 1,500 Class II and Class III medical device registration certificates, and 10 innovative products have entered the national “green channel” for innovative medical devices.

The industrial park has established close industry-academia-research collaborations with key universities and institutes. It hosts specialized major research institutions and innovative service platforms, such as the Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, and the Southeast University Suzhou Medical Device Research Institute. It is home to Jiangsu Province’s only High-End Medical Device Technology Innovation Center. The park has introduced a number of testing and inspection platforms, including the National Key Laboratory for Intelligent Medical Device Research and Evaluation, the Suzhou Branch of the Jiangsu Provincial Medical Device Testing Institute, the Suzhou New District Workstation of the Provincial Medical Products Administration for Review and Inspection, and the Soochow University Passive Device Testing Platform. Additionally, it has built a one-stop service center dedicated to serving high-end medical device enterprises, providing comprehensive and all-encompassing support.

Adhering to the development philosophy of “Integration and Innovation,” the Jiangsu Medical Device Technology Industrial Park will implement an operational model characterized by ecological development, industrial clustering, fund-based investment promotion, specialized services, market-oriented platforms, self-owned carriers, asset securitization, and digitalized operations and maintenance. Its goal is to establish Medpark as the leading brand in China’s medical device industry and build a trillion-yuan-level medical device industrial base.

WinX Capital is a leading investment bank in China’s healthcare industry, headquartered in Beijing and Shanghai, with offices in Shenzhen and Hangzhou. It has received numerous accolades, including Qimingpian’s “No. 1 Financial Advisor in the Healthcare Sector for 2024,” Diyixinsheng’s “No. 1 Financial Advisory Firm in the Healthcare Sector for 2022–2024,” and VCBeat’s “Annual Healthcare Financial Advisor” as part of its “Top 100 Future Healthcare Companies (2022–2024).”